Posts By: Candice

Cassini® successfully closes financing round

Cassini, a pioneer in the development of corneal diagnostic solutions, announced today that it has closed a Series A financing round with venture capital fund Innovation Industries. The injection of capital will accelerate the development and successful commercialization of Cassini, a diagnostic platform for premium refractive cataract surgery procedures.

Record 12 clinical studies on improving cataract surgery outcomes with Cassini® to be presented during ESCRS

Twelve clinical studies on improving outcomes of cataract surgery with Cassini, a novel diagnostic platform based on multi-color LED technology, will be presented at the upcoming ESCRS meeting in Lisbon, Portugal from October 7-11, 2017. The studies cover a wide range of research interests, including measurement of the posterior cornea, femtosecond laser assisted arcuate incisions for treatment of astigmatism and comparative studies of Cassini and other diagnostic technologies.

Cassini receives KFDA clearance for South Korea

Cassini announced today that it has obtained approval to market the Cassini corneal shape analyzer in South Korea (ROK). This is another important milestone in the International expansion of Cassini.

Cassini to present at the Ophthalmology Futures Forum in Singapore

Cassini has received the distinction to present at the Ophthalmology Futures Asian Forum which is held on March 1st 2017 in Singapore. The event connects scientists, entrepreneurs, physicians, regulators, corporate leaders and venture capitalists to drive innovation within the eye-care market.

Cassini features among most promising private ophthalmology companies at Ophthalmology Innovation Summit (OIS@ASCRS) in New Orleans, LA

Mark Packer MD, Chief Medical Officer will highlight Cassini as core technology in today’s refractive cataract surgery ecosystem. Cassini enables seamless integration of clinic and operating suite, from preoperative diagnostics through visualization and laser applications to postoperative analysis. Cassini data demonstrate 94.0% reduction of astigmatism to target, 0.50 Diopter or less. These results help increase the adoption of premium cataract surgery and Advanced Technology IOL’s.